United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.64M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $587.00 to $597.33 a share (average $593.52) in 11 transactions, worth $5.64M in total on Nov 12, 2026. Shares held after the trade: 324,443 (-0.1%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.64M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $584.20 to $598.63 a share (average $593.99) in 14 transactions, worth $5.64M in total on Nov 11, 2026. Shares held after the trade: 324,443 (-0.1%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.57M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $577.52 to $592.93 a share (average $586.32) in 14 transactions, worth $5.57M in total on Nov 10, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $944K of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 1,614 shares of United Therapeutics Corp at $583.80 to $585.63 a share (average $584.59) in 3 transactions, worth $944K in total on Nov 9, 2026. Shares held after the trade: 324,443 (-0.1%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.52M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 7,886 shares of United Therapeutics Corp at $556.52 to $582.79 a share (average $572.69) in 24 transactions, worth $4.52M in total on Nov 9, 2026. Shares held after the trade: 326,057 (-0.5%).
United Therapeutics Director Christopher Patusky Sells $702K of Stock
Christopher Patusky, Director, sold 1,210 shares of United Therapeutics Corp at $580.00 a share, worth $702K in total on Nov 9, 2026. Shares held after the trade: 2,140 (-36.1%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.36M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $560.79 to $568.68 a share (average $564.51) in 9 transactions, worth $5.36M in total on Nov 6, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $1.17M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 1,950 shares of United Therapeutics Corp at $593.14 to $602.49 a share (average $597.75) in 8 transactions, worth $1.17M in total on Nov 5, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.33M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 7,540 shares of United Therapeutics Corp at $562.51 to $591.54 a share (average $573.89) in 24 transactions, worth $4.33M in total on Nov 5, 2026. Shares held after the trade: 326,403 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $1.05M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 1,723 shares of United Therapeutics Corp at $610.29 to $613.13 a share (average $611.06) in 4 transactions, worth $1.05M in total on Nov 4, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.66M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 7,777 shares of United Therapeutics Corp at $580.70 to $609.09 a share (average $599.64) in 24 transactions, worth $4.66M in total on Nov 4, 2026. Shares held after the trade: 326,166 (-0.4%).
United Therapeutics EVP & General Counsel Paul A. Mahon Sells $4.97M of Stock
Paul A. Mahon, EVP & General Counsel, sold 8,300 shares of United Therapeutics Corp at $593.90 to $602.72 a share (average $598.67) in 9 transactions, worth $4.97M in total on Nov 5, 2026. Shares held after the trade: 45,172 (-2.4%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.72M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $598.68 to $605.97 a share (average $601.92) in 8 transactions, worth $5.72M in total on Nov 3, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics reported third quarter 2026 total revenues of $832.5 million, a 4% increase year-over-year, driven primarily by growth in Tyvaso DPI and Orenitram sales. Net income for the quarter was $258.6 million, or $5.71 per diluted share, representing a 24% decrease compared to the prior year period.
Term
Q3 2026
“United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve.”
Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics
“Our record third quarter revenue performance reflects a business operating at a very high level, driven by strong commercial momentum and focused execution across our organization.”
Michael Benkowitz, President and Chief Operating Officer of United Therapeutics
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.66M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $593.09 to $598.84 a share (average $596.22) in 7 transactions, worth $5.66M in total on Nov 2, 2026. Shares held after the trade: 324,443 (-0.1%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.7M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $594.92 to $608.05 a share (average $600.09) in 13 transactions, worth $5.7M in total on Oct 30, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.65M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $590.43 to $599.30 a share (average $594.78) in 9 transactions, worth $5.65M in total on Oct 29, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.56M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $583.50 to $588.39 a share (average $585.49) in 6 transactions, worth $5.56M in total on Oct 28, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.58M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $582.66 to $592.84 a share (average $587.73) in 11 transactions, worth $5.58M in total on Oct 27, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.59M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $585.71 to $592.92 a share (average $588.64) in 8 transactions, worth $5.59M in total on Oct 26, 2026. Shares held after the trade: 324,443 (-0.2%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.54M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $577.68 to $588.00 a share (average $582.76) in 11 transactions, worth $5.54M in total on Oct 23, 2026. Shares held after the trade: 324,443 (-0.2%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.54M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $562.97 to $590.40 a share (average $583.38) in 21 transactions, worth $5.54M in total on Oct 22, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.32M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $552.52 to $566.43 a share (average $560.07) in 14 transactions, worth $5.32M in total on Oct 21, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics' Board of Directors authorized a new $2.0 billion share repurchase program for its common stock. The authorization is effective for one year through October 21, 2027, and allows for repurchases via open market transactions, accelerated share repurchase programs, or private deals.
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.26M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $546.84 to $563.56 a share (average $553.87) in 17 transactions, worth $5.26M in total on Oct 20, 2026. Shares held after the trade: 324,443 (-0.1%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.16M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $534.75 to $556.88 a share (average $543.32) in 19 transactions, worth $5.16M in total on Oct 19, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.08M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $530.48 to $543.85 a share (average $534.66) in 13 transactions, worth $5.08M in total on Oct 16, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.19M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $540.48 to $551.50 a share (average $546.65) in 12 transactions, worth $5.19M in total on Oct 15, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics EVP & General Counsel Paul A. Mahon Sells $4.52M of Stock
Paul A. Mahon, EVP & General Counsel, sold 8,300 shares of United Therapeutics Corp at $541.64 to $546.56 a share (average $544.30) in 6 transactions, worth $4.52M in total on Oct 15, 2026. Shares held after the trade: 45,172 (-1.6%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.13M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $526.07 to $546.00 a share (average $539.99) in 16 transactions, worth $5.13M in total on Oct 14, 2026. Shares held after the trade: 324,443 (-0.0%).